Renal disease News and Research

RSS

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

Researchers at Wayne State University have discovered a potential way to improve the lipid profiles in patients undergoing hemodialysis that may prevent cardiovascular disease common in these patients.

16 Jan 2014

New study examines factors that may lead to end stage renal disease

About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease, at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure.

15 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

Life-threatening blood clots occur so rarely in children that the condition, known as venous thromboembolism (VTE), is often not on pediatricians' mental radar screens - an absence that can lead to woefully delayed recognition and treatment.

12 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

The prevalence of chronic fatigue syndrome in children and the significant impairment it causes to their physical functioning, school attendance and performance, and extracurricular activities, are at the root of a new Chicago-based study led by DePaul University psychologist Leonard A. Jason.

11 Dec 2013

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Patient Engagement Systems, a nationally recognized leader in developing technology to identify, and monitor individuals with chronic kidney disease, today introduced the Patient Engagement Systems' ESRD Prevention Program which uses proprietary technology including automated physician-patient engagement, analytics, and decision support tools to identify patients with undiagnosed chronic kidney disease and tools to monitor them in order to prevent or delay the progression to ESRD.

3 Dec 2013

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

First Nations adults with diabetes have more than double the risk of end-stage kidney disease compared with non-First Nations adults, found a new study in CMAJ (Canadian Medical Association Journal).

3 Dec 2013

African Americans have double the risk of end-stage renal disease compared to white Americans

In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients.

27 Nov 2013

Medical–surgical integration ‘boosts neoadjuvant chemotherapy use for bladder cancer’

Research from the USA indicates that a multidisciplinary approach and coordination between medical and surgical oncology services can help optimize the use of neoadjuvant chemotherapy for bladder cancer.

18 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Renal disease News and Research

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

New study examines factors that may lead to end stage renal disease

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

HCV antiviral therapy also improves diabetes outcomes

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

African Americans have double the risk of end-stage renal disease compared to white Americans

Medical–surgical integration ‘boosts neoadjuvant chemotherapy use for bladder cancer’

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Multiple pregnancies: A major public health concern worldwide

Genetic factors put African Americans with CKD at greater risk for end-stage renal disease

Study: Preeclampsia during pregnancy may be associated with increased risk of kidney failure

Genetic variations in African Americans with kidney disease contribute to rapid decline in kidney function

EKF Diagnostics to introduce upgraded POC analyzer and new sTNFr1 test kit at Medica 2013

Free guide - Everything about renal proximal tubule cells eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News